Lupin Ltd

Lupin Limited has informed the Exchange regarding a press release dated May 26, 2025, titled Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at theAmerican Society of Clinical Oncology - Annual Meeting 2025.